Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.39 |
| ▸ | CNR1 | P21554 | 9/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22023705 | 0.94 | CNR2 (0.44) | CNR2CNR1CYP19A1 | |
| SCHEMBL20927117 | 0.92 | CNR2 (0.47) | CNR2CNR1 | |
| SCHEMBL18381788 | 0.87 | CYP19A1 (0.40) | CNR2CNR1CYP19A1ESR1ESR2 | |
| SCHEMBL18382253 | 0.83 | CYP19A1 (0.38) | CNR2CNR1CYP19A1ESR1ESR2 | |
| SCHEMBL22169010 | 0.80 | CYP19A1 (0.36) | CYP19A1ESR1ESR2 | |
| SCHEMBL19245813 | 0.80 | CYP19A1 (0.40) | CYP19A1ESR1ESR2 | |
| SCHEMBL18909511 | 0.80 | CYP19A1 (0.36) | CNR2CNR1CYP19A1ESR1ESR2 | |
| SCHEMBL18852713 | 0.79 | CNR2 (0.37) | CNR2CNR1CYP19A1ESR1ESR2 | |
| SCHEMBL18721019 | 0.79 | CNR2 (0.37) | CNR2CNR1CYP19A1ESR1ESR2 | |
| SCHEMBL12523344 | 0.78 | CYP19A1 (0.47) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358967-B2 | Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-06-14 | — | — | US | disclosed |
| US-20210171527-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-06-10 | — | — | US | disclosed |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10793549-B2 | Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-10-06 | — | — | US | disclosed |
| US-10646492-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190298724-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2019-10-03 | — | — | US | disclosed |
| US-20190300506-A1 | SULFONYL-SUBSTITUTED BENZOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-10-03 | — | — | US | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | CNR2 1429/4885CNR1 1809/4885CYP19A1 503/4885 |
| US-20190300506-A1 | SULFONYL-SUBSTITUTED BENZOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF | STS, SLC5A2, SULT2A1 | CNR2 54/4885CNR1 109/4885CYP19A1 165/4885 |
| US-20170231999-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | CNR2 1429/4885CNR1 1809/4885CYP19A1 503/4885 |
| US-20210171527-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORC, RORB, RORA | CNR2 385/4885CNR1 250/4885CYP19A1 130/4885 |
| US-10646492-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | CNR2 1066/4885CNR1 1176/4885CYP19A1 526/4885 |
| US-20190298724-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CNR2 1066/4885CNR1 1176/4885CYP19A1 526/4885 |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | CNR2 4387/4885CNR1 4057/4885CYP19A1 231/4885 |
| US-10793549-B2 | Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereof | STS, SULT2A1, CYP2A13 | CNR2 77/4885CNR1 138/4885CYP19A1 150/4885 |
| US-11358967-B2 | Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma | RORC, RORB, RORA | CNR2 195/4885CNR1 221/4885CYP19A1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.